RxDoctor Payments DataLook up a doctor →

Brian Vicuna, MD

Medical Oncology · Las Vegas, NVNPI 1275755670

Payments from drug & device makers

$1,272,149in general payments, 2019–2025

Across 1,203 payments — averaging $1057.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$331K
  • Exelixis Inc.$254K
  • Ipsen Bioscience Inc.$176K
  • F. Hoffmann-la Roche AG$103K
  • GSK$97K
  • E.r. Squibb & Sons, L.L.C.$93K
  • plus $216K from 54 others
$1,006in research payments, 2019–2025

Across 2 payments — averaging $503.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.86$331,260
Exelixis Inc.44$254,403
Ipsen Bioscience Inc.33$176,309
F. Hoffmann-la Roche AG14$103,157
GSK71$96,549
E.r. Squibb & Sons, L.L.C.18$93,000
Eli Lilly7$48,056
Astellas Pharma Global Development51$32,722
Amgen54$26,427
AstraZeneca(2 entities)61$18,646
AbbVie42$15,273
Gilead(2 entities)22$10,327
Janssen Scientific Affairs, LLC9$6,551
Pfizer49$4,842
Taiho Oncology, Inc.4$4,307
Incyte Corporation20$4,152
Novartis73$4,070
Bristol Myers Squibb19$4,055
Ipsen Biopharmaceuticals, Inc12$3,541
Bayer24$3,380
Blueprint Medicines Corporation9$3,303
Takeda Pharmaceuticals U.S.A., Inc.9$2,313
Lilly USA, LLC12$2,288
ADC Therapeutics America, Inc.5$2,222
Hoffmann-la Roche Limited1$2,218
Johnson & Johnson(2 entities)50$2,210
Eisai Inc.6$1,902
Daiichi Sankyo Inc.93$1,686
Boehringer Ingelheim6$1,630
Array Biopharma Inc7$1,353
Aadi Bioscience, Inc.2$1,018
Beigene USA, Inc.6$823
Astellas Pharma US Inc22$727
Genentech USA, Inc.24$572
Beigene, Ltd.1$525
Sobi, Inc26$435
Sanofi18$423
Seagen Inc.14$403
Sanofi-aventis U.S. LLC4$350
EMD Serono, Inc.15$325
Jazz Pharmaceuticals Inc.5$307
Chiesi USA, Inc.1$300
AVEO Pharmaceuticals, Inc.5$286
Merck14$279
Tempus AI, Inc17$277
Karyopharm Therapeutics Inc.9$223
Pharmacyclics LLC, An Abbvie Company10$214
Dendreon Pharmaceuticals LLC8$201
Stemline Therapeutics Inc.6$178
Sumitomo Pharma America, Inc.7$165
Agios Pharmaceuticals, Inc.6$154
Sirtex Medical Inc1$146
Mirati Therapeutics, Inc.5$109
Regeneron Healthcare Solutions, Inc.5$102
Genmab U.S., Inc.4$98
Global Blood Therapeutics, Inc.4$83
Intuitive Surgical1$82
Rigel Pharmaceuticals, Inc.3$77
AMAG Pharmaceuticals, Inc.3$63
Dova Pharmaceuticals3$57

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,844,157
Medicare patients
908
Services billed
271,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Las Vegas

See the full list for Nevada →

Where these figures come from

Is this you, or does something look wrong? →